{"nctId":"NCT00291343","briefTitle":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","startDateStruct":{"date":"2006-02-01"},"conditions":["Infections, Meningococcal"],"count":296,"armGroups":[{"label":"TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™- HepB","Biological: Hiberix™","Biological: Mencevax™ ACWY"]},{"label":"TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Tritanrix™- HepB","Biological: Hiberix™","Biological: Mencevax™ ACWY"]}],"interventions":[{"name":"Tritanrix™- HepB","otherNames":[]},{"name":"Hiberix™","otherNames":[]},{"name":"Mencevax™ ACWY","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 15 and 24 months of age at the time of vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Having participated in the primary vaccination study DTPW-HBV=HIB-MENAC-TT-011 (eTrack No. 100478) in Center No. 4328 or Center No.4329.\n\nExclusion criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the vaccination, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of vaccination; with the exception of oral poliovirus vaccine (OPV).\n* Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib) and/or meningococcal serogroups A and/or C disease, after the date of the study conclusion visit of the primary vaccination study DTPW-HBV=HIB-MENAC-TT-011 (eTrack No. 100478).\n* History of diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A or C disease.\n* Known exposure to diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A or C disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* A family history of congenital or hereditary immunodeficiency.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures including febrile seizures in infancy.\n* Acute disease at the time of enrolment.\n* Planned or actual administration of immunoglobulins and/or any blood products within the three months preceding Mencevax™ ACWY vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"15 Months","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Serum Bactericidal Activity Against Neisseria Meningitidis Serogroups A, C (rSBA-MenA, C) Using Rabbit Complement Antibodies","description":"Antibody cut-offs were higher than or equal to (≥) 1:128","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-rSBA-MenA, C Antibody Titers ≥ Pre-defined Cut-off Values","description":"Pre-defined cut-offs were ≥ 1:8 and ≥ 1:128","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-rSBA-MenA, C Antibody Titers","description":"Antibody titers were expressed as Geometric Mean Titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"551.9","spread":null},{"groupId":"OG001","value":"469.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2018.9","spread":null},{"groupId":"OG001","value":"2108.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.6","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11024.4","spread":null},{"groupId":"OG001","value":"437.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pilysaccharide A and C (Anti-PSA/PSC) Antibody Concentrations ≥ Predefined Cut-off Values","description":"Antibody cut-offs were ≥ 0.3, 2 micrograms per millilitre (µg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSA, Anti-PSC Antibody Concentrations","description":"Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.54","spread":null},{"groupId":"OG001","value":"6.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.13","spread":null},{"groupId":"OG001","value":"20.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-hepatitis B Surface (Anti-HBs) Antigen Antibody Concentrations ≥ Cut-offs","description":"The antibody concentrations cut-off was ≥ 10 milli international units per millilitre (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Concentrations","description":"Antibody concnetrations were expressed as Geometric Mean Concentrations (GMCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251.1","spread":null},{"groupId":"OG001","value":"279.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Vaccine Response for rSBA-Men A, C","description":"Vaccine response was defined as follows: for initially seronegative subjects (i.e. with rSBA titer \\< 1:8 pre-vaccination), rSBA titer ≥ 1:32 post-vaccination (seroconversion), and for initially seropositive subjects (i.e. with rSBA \\> 1:8 prevaccination), at least a 4-fold increase in rSBA titer from pre-vaccination to post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness, swelling. Any = symptom occurring regardless of intensity grade.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, rectal fever \\[≥ 38 degrees Celsius (°C)\\]. Any = occurrence of symptom regardless of intensity grade.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regard-less of intensity grade or relation to vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":203},"commonTop":["Redness","Pain","Swelling","FEVER","IRRITABILITY"]}}}